US regulators have approved the first pill version of the weight-loss drug Wegovy, a move doctors in the UAE have welcomed as a major step in tackling obesity, while stressing the need for careful medical supervision. The US Food and Drug Administration cleared the daily oral form of the drug earlier this week, calling it a breakthrough in widening access to treatment. Wegovy, developed by Novo Nordisk, contains semaglutide and has shown average weight loss of more than 16 per cent in trials, similar to injections. UAE clinicians say the pill could improve convenience and adherence but warn it should not be seen as a quick fix. Experts stress it must be part of a supervised plan including diet, lifestyle changes and regular follow-up.
